DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Faropenem is an investigational drug.
There have been 8 clinical trials for Faropenem. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2005.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and Pneumonia, Bacterial. The leading clinical trial sponsors are Replidyne, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, and National University Hospital, Singapore.
Recent Clinical Trials for Faropenem
|Phase 2a Study Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB||Johns Hopkins University||Phase 2|
|Early Bactericidal Activity Study of Faropenem(With Amoxicillin/Clavulanic Acid)in Patients With Pulmonary Tuberculosis||National University Hospital, Singapore||Phase 2|
|Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers||National University Hospital, Singapore||Phase 1|